World's First Digital Atlas of the Human Liver Developed
Scientists from the Weizmann Institute and other centers have created a detailed digital atlas of the liver, which refutes the long-held concept of three zones and reveals eight distinct functional zones. This work, published in Nature, paves the way for more precise treatments for liver diseases, including fatty liver disease.
Digital Liver Atlas: Why the Discovery of Eight Zones Instead of Three Will Reshape the $38 Billion Hepatology Market
On April 15, 2026, the journal Nature published a study that shattered one of the most enduring dogmas in hepatology. Professor Shalev Itzkovitz from the Weizmann Institute, together with colleagues from Sheba Medical Center and Mayo Clinic, presented the world's first digital atlas of a healthy human liver with a resolution of 2 microns. Instead of the three functional zones described in textbooks for decades, the atlas revealed eight. This is not just an academic curiosity. It is a discovery that changes the rules of the game for pharma, diagnostics, and personalized medicine.
The Essence: What Is Really Happening
The atlas is based on samples from eight living donors—people who donated part of their liver for transplantation. The key word here is "healthy." Until now, liver studies relied on tissue adjacent to tumors or other pathological foci. Professor Itzkovitz is extremely clear in his formulation: "When you have cancer, even outside the liver, it completely reshapes the organ's metabolism." In other words, everything hepatology knew about "normal" was knowledge of pathologically altered tissue masquerading as healthy.
The technological foundation is a combination of single-cell RNA sequencing (analyzing gene activity of thousands of cells simultaneously) and high-resolution spatial mapping (spatial localization of each cell with an accuracy of 2 microns). For comparison, the thickness of a human hair is about 50 microns. The atlas resolution is 25 times finer than a hair.
And the first thing the atlas showed is that the human liver is radically different from that of mice, pigs, and cows. In all mammals except humans, metabolic activity is concentrated at the periphery of the liver lobule, where blood is rich in oxygen. In humans, it is exactly the opposite: cells in the center of the lobule perform the most energy-intensive tasks, including fat synthesis, glucose uptake, and detoxification.
Timeline and Context
The story didn't even start in 2026. The zonal model of the liver has been known since the 1970s–80s: three concentric zones, blood flows from the periphery to the center, oxygen deficiency in the center, cells there are less active. This model was reproduced in textbooks for decades and determined the design of preclinical studies.
April 2026. Publication in Nature. The data showed: "thousands of genes exhibit different activity in liver cells depending on their location, indicating a much more precise and complex internal organization than previously thought." Eight functional zones instead of three.
Important context: Itzkovitz's lab was damaged during the Iranian missile attack on the Weizmann Institute in June 2025. The researchers managed to "save the samples and complete the work." Without this scientific persistence, the atlas might not have happened.
Who Wins and Who Loses
Winners:
Pharmaceutical companies developing therapies for metabolic dysfunction-associated steatotic liver disease (MASLD) are the main beneficiaries. The MASLD therapy market is estimated at $38 billion, with dozens of molecules at various stages of clinical trials. The atlas has shown for the first time exactly where fat accumulates and why the central zones of the lobule are most vulnerable. This allows designing molecules that target specific genes in specific zones, reducing systemic side effects.
Transplantology and regenerative medicine gain a reference standard for a healthy liver. Surgeon and lead author Dr. Oran Yakubovsky, himself a transplantologist at Sheba Medical Center, emphasizes that the atlas provides a baseline for assessing the quality of a donor organ.
Diagnostic companies can develop tests that detect pathological changes at the zonal level long before clinical symptoms appear. Liquid biopsy with zonal specificity is a potential market of $1.5–2 billion.
Losers:
Manufacturers of drugs whose molecules were developed based on mouse models. The atlas showed that the mouse liver is structurally and functionally different from the human liver precisely in the distribution of activity zones. Drugs optimized for the mouse peripheral model may be suboptimal for the human central-oriented model. The researchers directly state that the discovery "challenges the exclusive use of animal models for studying liver diseases and reinforces the need to develop studies directly based on human tissues."
Laboratories without access to single-cell RNA sequencing and spatial mapping technologies find themselves at a methodological disadvantage. The atlas de facto sets a new standard for liver research, and publications without spatial resolution will increasingly struggle to pass peer review in Nature and Science.
What the Media Isn't Saying
Insight One: The Problem of "Sick Norm."
Most outlets reported the results but did not uncover the methodological bomb. If all previous studies used "healthy" tissue adjacent to pathology—and Itzkovitz claims that cancer "completely reshapes liver metabolism"—then the entire body of hepatological knowledge is built on a foundation of pathologically altered samples. About 70–80% of published data on "normal" liver physiology may need revision. This is not an exaggeration—it is a direct consequence of the methodological shift.
Insight Two: Kupffer Cells Moved.
The atlas discovered a phenomenon unique to humans: liver macrophages—Kupffer cells—in humans are concentrated in the center of the lobule, not at the periphery as in all other mammals. The researchers hypothesize that this is an adaptation to increased cellular wear in the central zones, which are the most metabolically active in humans. The cells "moved" to cope with the increased load of disposing of worn-out hepatocytes. This is an evolutionary compromise with no analog in laboratory animals.
Insight Three: A Defense Mechanism That Breaks.
The study showed that healthy liver cells, when accumulating fat, activate a protective response—they turn off genes for fat synthesis and uptake and activate genes for fat breakdown. But at the same time, fat suppresses the production of mitochondrial components that are supposed to break down these fats. This creates a vicious cycle: the liver tries to protect itself, but fat breaks the very tool of protection. This mechanism explains why some people develop steatohepatitis and others do not, and it is precisely this mechanism that can be targeted by therapy.
Insight Four: Diet vs. Evolution.
Professor Itzkovitz puts it bluntly: "The efficient division of labor in the liver was not designed for the modern diet rich in fats and carbohydrates." The central zones, which efficiently store glucose under conditions of scarcity, become a trap when glucose is abundant. This is an evolutionary mismatch—a mismatch between a metabolic program shaped by millennia of unstable nutrition and the reality of food abundance. The atlas provides a molecular map of this mismatch.
Forecast: Next 30 Days and 90 Days
30 Days (by mid-June 2026):
Labs like Karolinska Institute, Broad Institute, and Sanger Centre will start using the atlas as a reference for their own research. The citation count for the Nature article will exceed 100. Groups working with spatial transcriptomics will be the first to react—the atlas becomes the gold standard for validating their methods.
Pharma companies (Novo Nordisk, Eli Lilly, GSK, Madrigal Pharmaceuticals—all investing in MASLD/NAFLD therapy) will begin reviewing preclinical programs. Drug candidates will be tested not just "on hepatocytes" but on hepatocytes from specific zones.
90 Days (by mid-August 2026):
First research groups will publish data on zone-specific biomarkers for MASLD based on the atlas. Expect 3–5 preprints linking zonal gene expression to progression from steatosis to steatohepatitis.
Biotech startups will begin pitching "zonal therapy" to investors—drugs delivered specifically to the central zones of the liver lobule. Investment in this niche could reach $50–100 million by the end of the year.
The atlas methodology will be extended to other organs. Professor Itzkovitz directly states: "The approach of building a genetic atlas with single-cell resolution based on samples from living donors can be applied to other organs that have not yet been precisely mapped in humans." The kidney and pancreas are the first candidates.
Structural Forecast for 2–3 Years:
The atlas will change the design of clinical trials in hepatology. Instead of "reducing liver fat" as a general endpoint, zone-specific biomarkers will emerge. The FDA and EMA will have to adapt regulatory requirements: a drug that works in the central zones must be evaluated by central-zone markers.
The market for animal models in hepatology research will shrink. Investors will realize that a model not replicating human zonal architecture yields false negative or false positive results. The cost of translational failures due to mouse models in hepatology is estimated at $2–3 billion over the last decade. The atlas provides a tool to reduce these losses.
Most importantly, the atlas sets a precedent. If one organ required a revision of a 50-year dogma, how many more dogmas await their turn in the kidneys, pancreas, brain? The Weizmann Institute has just opened Pandora's box called "revision of anatomy through the lens of single-cell spatial biology." The next decade will show how deep this revision goes.
— Editorial Team
